Henning Nillius

22PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Sep 29, 2026
Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.

|Jul 15, 2026
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

|Jun 26, 2026
Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

|Mar 28, 2026
Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.

Maeva Ullmann, Katja Seipel, Henning Nilius

|Feb 27, 2026
Antibiotic Use Before CAR-T Treatment Is Associated with Inferior Outcomes in DLBCL Lymphoma Patients.

Anja Bullegas, Inna Shaforostova, Katja Seipel

|Oct 29, 2025
Clinical Impact of LAG3 Single-Nucleotide Polymorphism in DLBCL Treated with CAR-T Cell Therapy.

Katja Seipel, Sophia Maria Spahr, Inna Shaforostova

Pageof 4

Frequent Collaborators

13 joint publications

Ulrike Bacher

13 joint publications

Thomas Pabst

9 joint publications

Katja Seipel

7 joint publications

Michael Nagler